In a recent move at CTT Pharmaceutical Holdings, Inc. (OTCMKTS:CTTH), the company's CEO has made a notable acquisition of shares. The transaction, which took place on May 7, 2024, involved the purchase of 9,500 shares at a price of $0.04 each, totaling an investment of $380.
This purchase by the CEO, who holds a direct ownership in the shares, reflects a continued commitment to the company. Following the acquisition, the CEO now owns a total of 4,167,388 shares in CTT Pharmaceutical Holdings. The transaction was disclosed in a filing with the Securities and Exchange Commission on May 8, 2024.
Investors often keep a close watch on insider transactions as they can provide insights into the company's performance and management's confidence in the business. The recent acquisition by the CEO of CTT Pharmaceutical Holdings is a transaction of interest for those following the company's stock and developments.
CTT Pharmaceutical Holdings, with its business address in Tampa, Florida, operates in the gold and silver ores industry and is incorporated in Delaware. The company's shares are traded on the OTC Markets under the symbol CTTH.
InvestingPro Insights
Following the CEO's share acquisition at CTT Pharmaceutical Holdings, Inc. (OTCMKTS:CTTH), a closer look at the company's financial metrics and market performance offers additional context for investors. CTT Pharmaceutical Holdings is currently operating under a significant debt burden, which is a critical factor to consider as it may struggle with making interest payments on its debt. This is an essential consideration highlighted in the InvestingPro Tips for the company.
Despite the CEO's recent show of confidence, the company's stock has experienced notable fluctuations. According to InvestingPro Data, the 1 Week Price Total Return as of May 7, 2024, is an impressive 63.27%, reflecting a recent surge. However, a broader view shows a 1 Month Price Total Return of -27.27%, indicating recent volatility. Over the last year, the company's stock has seen a substantial increase with a 1 Year Price Total Return of 181.69%, yet it is currently trading at only 40.0% of its 52-week high.
Moreover, with a market capitalization of just 2.01M USD and a negative P/E Ratio of -0.464, CTT Pharmaceutical Holdings presents a complex investment profile. The company's stock is trading at a low Price / Book multiple, which is another InvestingPro Tip that prospective investors should take into account. For those looking to dive deeper into the financial details and additional tips, there are 13 more InvestingPro Tips available for CTTH, which can be accessed by visiting the company's page on InvestingPro. Investors can also benefit from an additional 10% off a yearly or biyearly Pro and Pro+ subscription using the coupon code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.